Edition:
India

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

121.90EUR
9:04pm IST
Change (% chg)

€1.75 (+1.46%)
Prev Close
€120.15
Open
€119.65
Day's High
€121.95
Day's Low
€119.00
Volume
54,244
Avg. Vol
122,300
52-wk High
€129.85
52-wk Low
€76.58

Latest Key Developments (Source: Significant Developments)

Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients
Wednesday, 17 Jan 2018 

Jan 16 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL.MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO.  Full Article

Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America
Friday, 12 Jan 2018 

Jan 12 (Reuters) - IPSEN SA ::IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA.  Full Article

Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - IPSEN SA ::‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​.‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​.‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​.‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​.  Full Article

Ipsen ‍reports Q3 2017 group sales growth of 22.6%​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - IPSEN SA ::‍Q3 2017 GROUP SALES GROWTH OF 22.6%​.‍FULL YEAR 2017 GUIDANCE CONFIRMED.Q3 GROUP SALES EUR ‍​470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO.  Full Article

Exelixis' Cabozantinib meets key goal in late-stage trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Exelixis Inc :Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma.Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​.Safety data in study were consistent with established profile of Cabozantinib​​.  Full Article

Ipsen receives validation from European Medicines Agency for application of new indication for Cabometyx
Monday, 11 Sep 2017 

Sept 11 (Reuters) - IPSEN SA ::ANNOUNCED ON FRIDAY, IPSEN RECEIVES VALIDATION FROM EUROPEAN MEDICINES AGENCY FOR THE APPLICATION OF A NEW INDICATION FOR CABOMETYX (CABOZANTINIB) FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN ADULTS.FILING IN FIRST LINE ARCC IS BASED ON THE CABOSUN RESULTS, A PHASE II TRIAL DEMONSTRATING THAT CABOMETYX PROLONGS PROGRESSION-FREE SURVIVAL (PFS) IN TREATMENT-NAIVE PATIENTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RCC COMPARED TO SUNITINIB.  Full Article

Ipsen and Exelixis announce Phase 2 results of CABOSUN trial
Monday, 11 Sep 2017 

Sept 10 (Reuters) - IPSEN SA ::ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.CABOZANTINIB PROVIDED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL, WITH A 52 PERCENT REDUCTION IN THE RATE OF PROGRESSION OR DEATH COMPARED TO SUNITINIB.  Full Article

Sanofi nearing deal to sell some over-the-counter products to Ipsen for about 100 mln euros- Bloomberg, citing source
Monday, 13 Feb 2017 

: Sanofi nearing agreement to sell some over-the-counter products to Ipsen; deal may be announced as soon as Monday- Bloomberg, citing source .Deal could be valued at almost 100 million euros- Bloomberg, citing source.  Full Article

Ipsen and Exelixis receive positive CHMP opinion for Cabometyx
Friday, 22 Jul 2016 

Ipsen SA : Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx (cabozantinib) for treatment of advanced renal cell carcinoma in adults . Cabometyx (cabozantinib) significantly improved overall survival across all evaluated patient subgroups .Recommendation will now be reviewed by the European Commission with a decision expected two months post CHMP opinion.  Full Article

Ipsen says EMA accepts marketing authorization application for telotristat etiprate
Monday, 18 Jul 2016 

Ipsen SA : Ipsen announces the acceptance by the european medicines agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues .Ipsen will pursue a worldwide regulatory plan for marketing authorization submissions in territories where it operates.  Full Article

French pharma group Ipsen sees more asset purchases, U.S. growth

PARIS French pharma company Ipsen expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros ($1.25 billion) for asset purchases, its chief executive said.